Nuwellis Reveals Aquadex System Success in Liver Disease
Company Announcements

Nuwellis Reveals Aquadex System Success in Liver Disease

Nuwellis (NUWE) has released an update.

Nuwellis, Inc. has announced significant findings showing the effectiveness of their Aquadex SmartFlow® system for patients with severe liver disease experiencing fluid overload. The press release detailing these results emphasizes the system’s potential benefits, marking a noteworthy development in the treatment of end-stage liver disease related complications.

For further insights into NUWE stock, check out TipRanks’ Stock Analysis page.

For a comprehensive understanding of the announcement, you can read the full document here.

Related Articles
GlobeNewswireNuwellis Announces First Pediatric Patient Treated in a Commercial Setting with SeaStar Medical’s QUELIMMUNE™ Therapy at Cincinnati Children’s
TipRanks Auto-Generated NewsdeskNuwellis Announces Equity Offering to Strengthen Finances
TheFlyNuwellis to sell 469,340 shares at $4.24 in registered direct offering
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Optimize your mobile reading experience. Download the TipRanks App today!